

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO.   | FILING DATE   | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.             | CONFIRMATION NO. |
|---|---------------|----------------------|---------------------------------|------------------|
| 09/498,046  | 02/04/2000    | Sabine Neirynck      | VIB-08                          | 8244             |
| 75  | 90 12/16/2002 |                      |                                 |                  |
| James F. Haley Jr.<br>Fish & Neave<br>1251 Avenue of the Americas |               |                      | EXAMINER                        |                  |
|   |               |                      | FOLEY, SHANON A                 |                  |
| New York, NY 10020-1104   |               |                      | ART UNIT                        | PAPER NUMBER     |
|   |               |                      | 1648<br>DATE MAILED: 12/16/2002 | 18               |

Please find below and/or attached an Office communication concerning this application or proceeding.

|   | Application No.  | Applicant(s)  |   |  |  |
|---|--|---|---|--|--|
| Advisory Action   | 09/498,046   | NEIRYNCK ET AL.   |   |  |  |
| ·   | Examin r   | Art Unit  |   |  |  |
|   | Shanon Foley   | 1648  |   |  |  |
| The MAILING DATE of this communication appe   | ars on the cover sheet with th   | orrespondence add                                       | ress                                    |  |  |
| THE REPLY FILED 11/4/2 and 11/12/2 FAILS TO PLAC Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appears Examination (RCE) in compliance with 37 CFR 1.114.   | void abandonment of this applic<br>) a timely filed amendment whi  | cation. A proper rep<br>ch places the applic            | oly to a cation in                      |  |  |
| PERIOD FOR RE   | PLY [check either a) or b)]  |   |   |  |  |
| a) The period for reply expires <u>4</u> months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  | isory Action, or (2) the date set forth in the<br>an SIX MONTHS from the mailing date of<br>FILED WITHIN TWO MONTHS OF THE | f the final rejection.<br>E FINAL REJECTION. S          | See MPEP                                |  |  |
| Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moleanned patent term adjustment. See 37 CFR 1.704(b). | sion and the corresponding amount of the<br>statutory period for reply originally set in                                   | fee. The appropriate ext<br>the final Office action; or | ension fee under<br>(2) as set forth in |  |  |
| 1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CF   |  |   |   |  |  |
| $2. \boxtimes$ The proposed amendment(s) will not be entered be   | ecause:  |   |   |  |  |
| (a) X they raise new issues that would require further  | er consideration and/or search (   | see NOTE below);  |   |  |  |
| (b) they raise the issue of new matter (see Note b  | pelow);  |   |   |  |  |
| (c) they are not deemed to place the application i<br>issues for appeal; and/or   | n better form for appeal by mat  | erially reducing or s                                   | simplifying the                         |  |  |
| (d) M they present additional claims without cancel   | ing a corresponding number of  | finally rejected clair                                  | ms.                                     |  |  |
| NOTE: See Continuation Sheet.   | •  |   |   |  |  |
| 3. Applicant's reply has overcome the following rejection   | tion(s):   |   |   |  |  |
| 4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).   | be allowable if submitted in a s   | eparate, timely file                                    | d amendment                             |  |  |
| 5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request fo application in condition for allowance because:   |  | sidered but does NO                                     | OT place the                            |  |  |
| 6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.  | cause it is not directed SOLELY  | to issues which we                                      | ere newly                               |  |  |
| 7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims w  | $\mathbf{x}(\mathbf{s})$ a) $oxtimes$ will not be entered or bould be rejected is provided below                           | o)  will be entered<br>ow or appended.                  | and an                                  |  |  |
| The status of the claim(s) is (or will be) as follows:  |  |   |   |  |  |
| Claim(s) allowed: none.   |  |   |   |  |  |
| Claim(s) objected to: none.   |  |   |   |  |  |
| Claim(s) rejected: 26-32,34-41,46 and 52-54.  |  |   |   |  |  |
| Claim(s) withdrawn from consideration: 42-45 and  | <u>47-51</u> .   |   |   |  |  |
| 8. The proposed drawing correction filed on is  | a) ☐ approved or b) ☐ disapp   | proved by the Exan                                      | niner.                                  |  |  |
| 9. Note the attached Information Disclosure Stateme   | nt(s)( PTO-1449) Paper No(s).  | <u></u> •   |   |  |  |
| 10. Other:  |  |   |   |  |  |
| <del></del>   |  |   |   |  |  |
|   |  |   |   |  |  |
|   |  |   |   |  |  |

## continuation Sh et (PTO-303)



Continuation of 2. NOTE: Although it is appreciated that applicant included "immunogenic" and specific proteins of other influenza viruses, claim 26 has been amended to broaden the scope of the "extracellular part" of the M2 protein that is not limited to the portion taught in the specification. This broadened "extracellular part" would require a new prior art search as well as a new consideration unde 35 USC 112.

Show toly

MARY E. MOSHER PRIMARY EXAMINER GROUP 1800

1600